Business
The ASX health giant riding COVID’s second wave – The Australian Financial Review
Fisher & Paykel Healthcare’s humidifiers have become vital to the treatment of COVID-19 cases. But investors are starting to look beyond the virus.
Operating revenue surged 59 per cent to $NZ910.2 million ($862.7 million) as earnings rose 86 per cent to $NZ225.5 million ($213.7 million).
Typically, the group has derived about 60 per cent of its revenue from selling hardware and associated consumables into hospitals, with the other 40 per cent from selling products for home care, particularly in the treatment of sleep apnoea.
But in the September half, 75 per cent of revenue came from the hospital side of the business. Hospital hardware sales…
-
Business16 hours agoA key reason why many ASX fund managers underperformed last financial year
-
Business13 hours agoWhat could happen to the big 4 banks in FY26?
-
Noosa News15 hours ago2025’s Melbourne International Film Festival Is Opening with the Rose Byrne-Starring ‘If I Had Legs I’d Kick You’
-
Noosa News16 hours agoCharity gala funds 18 vital pieces of peadiatric medical equipment